Industrifonden has recruited Yilmaz Mahshid as a new business analyst and investment manager for the Life Science business area. He was most recently employed by Pareto Securities.
Yilmaz Mahshid, 35, has a PhD in biochemistry from the Karolinska Institute. He has also worked with drug development at biotechnology companies. For the last six years Yilmaz has worked as a business analyst in life science, since 2011 at Pareto Securities, where he was responsible for all financial and market analysis of companies in pharmaceuticals, biotech and medical technology.
“Yilmaz will be an excellent addition to our team,” said Lennart Hansson, Investment Director for the Life Science business area at Industrifonden. “He has a very interesting skill set with experience from academic and industrial research and deep insight into the financial industry. We now have greater expertise and capacity to analyze the public and private life science market from an international perspective.”
Industrifonden is one of Sweden’s most active life science investors. The fund’s current holdings include Index Pharmaceuticals, Pharmalink, RxEye and Trialbee. Among successful exits in life science are CellaVision, Carmel Pharma and Bioinvent.
For more information, please contact
Lennart Hansson, Investment Director at Industrifonden, tel +46 706 31 00 31